Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Leases (2018 - 2025)

Summit Therapeutics (SMMT) has disclosed Current Leases for 7 consecutive years, with $2.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases fell 28.27% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Sep 2025, down 28.27%, and an annual FY2024 reading of $3.8 million, up 34.03% over the prior year.
  • Current Leases was $2.7 million for Q3 2025 at Summit Therapeutics, down from $3.1 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.8 million in Q3 2024 and bottomed at $684000.0 in Q2 2022.
  • Average Current Leases over 5 years is $2.3 million, with a median of $2.7 million recorded in 2025.
  • The sharpest move saw Current Leases crashed 32.01% in 2022, then soared 328.07% in 2023.
  • Year by year, Current Leases stood at $1.1 million in 2021, then surged by 54.9% to $1.7 million in 2022, then soared by 66.21% to $2.8 million in 2023, then surged by 34.03% to $3.8 million in 2024, then decreased by 27.76% to $2.7 million in 2025.
  • Business Quant data shows Current Leases for SMMT at $2.7 million in Q3 2025, $3.1 million in Q2 2025, and $3.5 million in Q1 2025.